National Institutes of Health to Grant Exclusive Option License for Mesothelin Antibody Treatment

Summary

The National Institutes of Health is considering granting an exclusive start-up option license to H2Bio, Inc. for the development of a single domain human anti-mesothelin monoclonal antibody for treating human cancers, as outlined in U.S. Patent Applications and related patents.